

ZIOPHARM ONCOLOGY INC  
Form 8-K  
October 08, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (date of earliest event reported): October 7, 2008

**ZIOPHARM Oncology, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Delaware	0-32353	84-1475642
(State or Other	(Commission	(IRS
Jurisdiction of	File	Employer
Incorporation)	Number)	Identification
		No.)

**1180 Avenue of the Americas, 19th Floor  
New York, NY 10036**

(Address of Principal Executive Offices) (Zip Code)

**(646) 214-0700**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01. Other Events.**

ZIOPHARM Oncology has taken actions aimed at reducing operating expenses in a continued effort to efficiently manage the Company's resources given the current economic environment. These actions include staff elimination (eight) and other employee- and product-related discretionary cost reductions. In light of these steps, the Company currently expects its cash and cash equivalents to fund operations very early into the first quarter of 2010. The Company previously projected that its cash and cash equivalents would be sufficient to fund operations into the third quarter of 2009.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.:  
(REGISTRANT)

Date: October 8, 2008

By:

/s/ Richard E. Bagley  
RICHARD E. BAGLEY, *President, Chief  
Operating Officer*

---